Amgen, Inc. (NASDAQ:AMGN) Shares Sold by TRUE Private Wealth Advisors

TRUE Private Wealth Advisors lessened its holdings in Amgen, Inc. (NASDAQ:AMGN) by 8.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,456 shares of the medical research company’s stock after selling 316 shares during the quarter. TRUE Private Wealth Advisors’ holdings in Amgen were worth $668,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Advisors Preferred LLC acquired a new position in Amgen in the 2nd quarter worth approximately $30,000. Arbor Wealth Management LLC boosted its position in Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock worth $31,000 after purchasing an additional 102 shares in the last quarter. Ashburton Jersey Ltd purchased a new stake in Amgen in the 2nd quarter worth approximately $42,000. Sound Income Strategies LLC boosted its position in Amgen by 402.1% in the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock worth $43,000 after purchasing an additional 189 shares in the last quarter. Finally, Next Capital Management LLC boosted its position in Amgen by 42.5% in the 2nd quarter. Next Capital Management LLC now owns 238 shares of the medical research company’s stock worth $44,000 after purchasing an additional 71 shares in the last quarter. Institutional investors own 76.24% of the company’s stock.

Shares of NASDAQ:AMGN traded up $0.32 during midday trading on Wednesday, reaching $196.40. 215,888 shares of the company’s stock traded hands, compared to its average volume of 2,991,597. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $211.90. The company has a market cap of $117.30 billion, a P/E ratio of 13.64, a PEG ratio of 2.54 and a beta of 1.11. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89. The company has a fifty day simple moving average of $199.86 and a two-hundred day simple moving average of $186.12.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter last year, the firm posted $3.83 EPS. The business’s revenue was down 3.1% on a year-over-year basis. As a group, research analysts forecast that Amgen, Inc. will post 14.31 EPS for the current fiscal year.

AMGN has been the topic of several recent research reports. Goldman Sachs Group set a $243.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Monday, September 30th. Evercore ISI restated a “hold” rating on shares of Amgen in a research report on Sunday, August 11th. BMO Capital Markets set a $240.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Monday, September 30th. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Mizuho restated a “hold” rating and issued a $212.00 price objective on shares of Amgen in a research report on Sunday, September 29th. Eleven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Amgen has a consensus rating of “Hold” and a consensus target price of $217.41.

In other Amgen news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the transaction, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $206.70, for a total value of $413,400.00. Following the completion of the transaction, the director now owns 16,336 shares in the company, valued at approximately $3,376,651.20. The disclosure for this sale can be found here. Insiders have sold a total of 17,851 shares of company stock worth $3,671,900 in the last quarter. Insiders own 0.25% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Day Trading – Risk Worth the Reward?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.